Precision Biosciences (DTIL) Net Income (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Net Income of -$8.6 million for Q1 2026, up 59.69% year-over-year from -$5.4 million in Q1 2025, and down 165.96% quarter-over-quarter from $13.0 million in Q4 2025.
Precision Biosciences (DTIL) Net Income (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Net Income for 9 consecutive years, with -$8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income rose 59.69% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$45.4 million (up 23.13% YoY), while the FY2025 annual figure was $885000.0, changed N/A from the prior year.
- Net Income retreated to -$8.6 million in Q1 2026 per DTIL's latest filing, from $13.0 million in the prior quarter.
- Across five years, Net Income topped out at $15.6 million in Q2 2024 and bottomed at -$35.9 million in Q2 2022.
- Historically, Net Income has averaged -$12.6 million across 5 years, with a median of -$9.1 million in 2022.
- On a YoY basis, Net Income climbed as much as 275.73% in 2024 and fell as far as 830.94% in 2024.
- Precision Biosciences' Net Income stood at -$9.1 million in 2022, then jumped by 68.49% to -$2.9 million in 2023, then slumped by 736.22% to -$23.9 million in 2024, then jumped by 154.45% to $13.0 million in 2025, then tumbled by 165.96% to -$8.6 million in 2026.
- Business Quant data shows DTIL's Net Income at -$8.6 million in Q1 2026, $13.0 million in Q4 2025, and -$27.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -18.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.73 Mn |
| Mar 31, 2026 | -8.58 Mn |
| Dec 31, 2025 | 13.00 Mn |
| Sep 30, 2025 | -27.65 Mn |
| Jun 30, 2025 | -22.17 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -23.87 Mn |
| Sep 30, 2024 | -29.46 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -2.86 Mn |
| Sep 30, 2023 | 4.03 Mn |
| Jun 30, 2023 | -8.86 Mn |
| Mar 31, 2023 | -11.11 Mn |
| Dec 31, 2022 | -9.06 Mn |
| Sep 30, 2022 | -8.26 Mn |
| Jun 30, 2022 | -35.86 Mn |
| Mar 31, 2022 | -34.23 Mn |
| Dec 31, 2021 | -30.71 Mn |
| Sep 30, 2021 | -22.12 Mn |